Published in Med Res Rev on January 01, 1999
Aldose reductase-deficient mice develop nephrogenic diabetes insipidus. Mol Cell Biol (2000) 1.14
Proteome wide reduction in AGE modification in streptozotocin induced diabetic mice by hydralazine mediated transglycation. Sci Rep (2013) 0.89
Non-invasive continuous glucose monitoring with multi-sensor systems: a Monte Carlo-based methodology for assessing calibration robustness. Sensors (Basel) (2013) 0.81
Discovery of novel PTP1B inhibitors with antihyperglycemic activity. Acta Pharmacol Sin (2010) 0.79
Structural and thermodynamic studies of simple aldose reductase-inhibitor complexes. Bioorg Chem (2006) 0.77
Systemic and ocular pharmacokinetics of N-4-benzoylaminophenylsulfonylglycine (BAPSG), a novel aldose reductase inhibitor. J Pharm Pharmacol (2004) 0.77
Synthesis and Biological Evaluation of Novel Gigantol Derivatives as Potential Agents in Prevention of Diabetic Cataract. PLoS One (2015) 0.77
Probenecid treatment enhances retinal and brain delivery of N-4-benzoylaminophenylsulfonylglycine: an anionic aldose reductase inhibitor. Brain Res Bull (2009) 0.75
Euonymus alatus: A Review on Its Phytochemistry and Antidiabetic Activity. Evid Based Complement Alternat Med (2016) 0.75
Bioactivity Focus of α-Cyano-4-hydroxycinnamic acid (CHCA) Leads to Effective Multifunctional Aldose Reductase Inhibitors. Sci Rep (2016) 0.75
Tunable Fröhlich polarons in organic single-crystal transistors. Nat Mater (2006) 2.74
Anatomic observations on complete form of persistent common atrioventricular canal with special reference to atrioventricular valves. Mayo Clin Proc (1966) 1.78
Generation of specific deoxynojirimycin-type inhibitors of the non-lysosomal glucosylceramidase. J Biol Chem (1998) 1.56
Diuretic agents related to indapamide. 1. Synthesis and activity of 1-substituted 2-(4-chloro-3-sulfamoylbenzamido)isoindolines. J Med Chem (1981) 1.36
2,6-Dialkylpiperazines. V. Synthesis of 2,6-alkylpiperazine derivatives structurally related to cinnarazine. J Med Chem (1968) 1.23
Role of GABA(B) receptors in the sedative/hypnotic effect of gamma-hydroxybutyric acid. Eur J Pharmacol (2001) 1.15
Thymidylate synthase structure, function and implication in drug discovery. Curr Med Chem (2005) 1.06
Synthesis, activity, and molecular modeling of a new series of tricyclic pyridazinones as selective aldose reductase inhibitors. J Med Chem (1996) 1.04
Angiocardiography of persistent common atrioventricular canal. Mayo Clin Proc (1967) 1.01
Structure-based design of inhibitors specific for bacterial thymidylate synthase. Biochemistry (1999) 0.98
Activity of polyphenolic crude extracts as scavengers of superoxide radicals and inhibitors of xanthine oxidase. Planta Med (1992) 0.97
Semicarbazide-sensitive amine oxidase/vascular adhesion protein 1: recent developments concerning substrates and inhibitors of a promising therapeutic target. Curr Med Chem (2008) 0.96
Semicarbazide-sensitive amine oxidase: current status and perspectives. Curr Med Chem (2004) 0.90
Effect of methadone on TSH and thyroid hormone secretion. Horm Metab Res (1984) 0.84
Isoxazolo-[3,4-d]-pyridazin-7-(6H)-one as a potential substrate for new aldose reductase inhibitors. J Med Chem (1999) 0.83
The opioid-receptor-like 1 (ORL-1) as a potential target for new analgesics. Eur J Med Chem (2000) 0.81
Phthalein derivatives as a new tool for selectivity in thymidylate synthase inhibition. J Med Chem (1999) 0.81
Designed multiple ligands: basic research vs clinical outcomes. Curr Med Chem (2012) 0.81
Gamma-hydroxybutyric acid (GHB) and the mesoaccumbens reward circuit: evidence for GABA(B) receptor-mediated effects. Neuroscience (2005) 0.80
Selective ACAT inhibitors as promising antihyperlipidemic, antiathero-sclerotic and anti-Alzheimer drugs. Mini Rev Med Chem (2003) 0.79
Isoxazolo-[3,4-d]-pyridazin-7-(6H)-ones and their corresponding 4,5-disubstituted-3-(2H)-pyridazinone analogues as new substrates for alpha1-adrenoceptor selective antagonists: synthesis, modeling, and binding studies. Bioorg Med Chem (1998) 0.79
Study of the antisecretory and antiulcer mechanisms of a new indenopirydazinone derivative in rats. Pharmacol Res (1997) 0.78
Oxidative modification of aldose reductase induced by copper ion. Factors and conditions affecting the process. Biochemistry (1998) 0.78
Mono- and disubstituted-3,8-diazabicyclo[3.2.1]octane derivatives as analgesics structurally related to epibatidine: synthesis, activity, and modeling. J Med Chem (1998) 0.78
Platelet alpha2-adrenoceptor alterations in patients with essential hypertension. Br J Clin Pharmacol (1999) 0.77
Effects of dopamine receptor stimulation on opiate-induced modifications of pituitary-gonadal function. Horm Res (1985) 0.77
Synthesis and pharmacological study of 5-aryl-6-methyl-4,5-dihydro-pyridazin-3(2H)ones and related 5-aryl-6-methyl-pyridazin-3(2H)ones. Farmaco Sci (1988) 0.77
Pyridoxine (Vit. B6) decreases opioids-induced hyperprolactinemia. Horm Metab Res (1985) 0.77
Phenylpiperazinylalkylamino substituted pyridazinones as potent alpha(1) adrenoceptor antagonists. J Med Chem (2001) 0.77
1-Benzopyran-4-one antioxidants as aldose reductase inhibitors. J Med Chem (1999) 0.77
Synthesis and cytotoxicity of bis(benzo[g]indole-3-carboxamides) and related compounds. Arch Pharm (Weinheim) (2001) 0.76
Calcitonin inhibition of growth hormone-releasing hormone-induced GH secretion in normal men. Acta Endocrinol (Copenh) (1989) 0.76
5,6-Diphenylpyridazine derivatives as acyl-CoA:cholesterol acyltransferase inhibitors. J Med Chem (2001) 0.76
Anthocyanidines as inhibitors of xanthine oxidase. Pharmazie (1995) 0.76
Aldose reductase does catalyse the reduction of glyceraldehyde through a stoichiometric oxidation of NADPH. Exp Eye Res (2000) 0.76
[Comparative study in normal man of the turnover of L-thyroxine and of its dextro isomer]. Acta Isot (Padova) (1964) 0.75
Synthesis and pharmacological activity of 4-carbamoyl-5-aryl-6-methyl-4,5-dihydropyridazin-3(2H)-ones. Farmaco (1992) 0.75
Interaction of 3,8-diazabicyclo (3.2.1) octanes with mu and delta opioid receptors. Pharmacol Res Commun (1988) 0.75
New congeners of antihypertensive and antithrombotic 7-amino or 7-acetyl-aminosubstituted-4,4a-dihydro-5H-indeno (1,2-c)pyridazin-3-ones. Farmaco Sci (1988) 0.75
Synthesis and pharmacological evaluation of a new class of 2-oxo-8-azaspiro (4,5)decan-1-ones as analogues of the muscarinic agonist RS-86. Farmaco (1993) 0.75
Pharmacokinetics and distribution of sodium 3,4-diaminonaphthalene-1-sulfonate, a Congo Red derivative active in inhibiting PrP(res) replication. J Pharm Pharmacol (2004) 0.75
Activation of PRL secretion by combined treatment with cyproterone acetate and ethinylestradiol. J Endocrinol Invest (1985) 0.75
Characterization and pharmacological actions of tecostanine, an alkaloid of Tecoma stans. Pharmazie (2003) 0.75
Synthesis, modelling, and mu-opioid receptor affinity of N-3(9)-arylpropenyl-N-9(3)-propionyl-3,9-diazabicycl. Farmaco (2000) 0.75
Classical and new proving methodology: provings of Plumbum metallicum and Piper methysticum and comparison with a classical proving of Plumbum metallicum. Homeopathy (2005) 0.75
Indenopyridazinone derivatives as potential antisecretory and antiulcer agents. Drug Des Discov (1997) 0.75
Bicyclic homologs of piperazine. IX. Synthesis and pharmacological properties of phenothiazine and of 10,11-dihydrodibenzocycloheptene derivatives of 3,8-diazabicyclo[3.2.1]octanes. J Med Chem (1969) 0.75
Fate of papillary muscles after prosthetic replacement of mitral valve. Mayo Clin Proc (1967) 0.75
7-Hydroxy-2-substituted-4-H-1-benzopyran-4-one derivatives as aldose reductase inhibitors: a SAR study. Eur J Med Chem (2001) 0.75
Antinociceptive action of DBO 17 and DBO 11 in mice: two 3,8 diazabicyclo (3.2.1.) octane derivates with selective mu opioid receptor affinity. Naunyn Schmiedebergs Arch Pharmacol (1997) 0.75
[Derivatives of phenylbutyrrolactones. II. 3,3'-diphenyl-N,N-dipyrrolidin-2,2'-dione: separation and chemical behavior of the diastereoisomers]. Farmaco Sci (1966) 0.75
Acute and chronic hyperbaric oxygen exposure in humans: effects on blood polyamines, adrenocorticotropin and beta-endorphin. Acta Endocrinol (Copenh) (1993) 0.75
[Diabetes insipidus after selective pituitary adenomectomy. A case with late appearance]. Minerva Med (1987) 0.75
NF-kappaB and AP-1 gene expression inhibitors. Drug Discov Today (2001) 0.75
[Neuroendocrine changes in subjects undergoing hyperbaric treatment]. Minerva Anestesiol (1991) 0.75
2,6-dialkylpiperazines. VII-Synthesis of N4-(2'-pyridyl)-2,6-dimethylpiperazine and separation of its geometrical isomers. Farmaco Sci (1976) 0.75
Benzocondensed derivatives as rigid analogues of the mu-opioid agonist 3(8)-cinnamyl-8(3)-propionyl-3,8-diazabicyclo[3.2.1]octanes: synthesis, modeling, and affinity. Farmaco (1999) 0.75
Preparation of thieno[3,2-h]cinnolinones as matrix metalloproteinase inhibitors. Arch Pharm (Weinheim) (2000) 0.75
2,6-Dialkylpiperazines. IV. 1-Propionyl-4-substituted cis-2,6-dimethylpiperazines structurally related to the analgetic 8-acyl-3,8-diazabicyclo[3.2.1]octanes. J Med Chem (1968) 0.75
Synthesis and D2-like binding affinity of 4,5-dihydro-1H-benzo[g]indole-3-carboxamide derivatives as conformationally restricted 5-phenyl-pyrrole-3-carboxamide analogs. Farmaco (1999) 0.75
[Study of Fiedler's primary interstitial myocarditis (report of 2 cases)]. Pediatria (Napoli) (1971) 0.75
Synthesis and mu-opioid receptor affinity of a new series of nitro substituted 3,8-diazabicyclo[3.2.1]octane derivatives. Farmaco (1999) 0.75
Non peptidic ligands at the opioid receptor like-1 (ORL-1). Mini Rev Med Chem (2001) 0.75
[C-alkylpiperazines. XII. Synthesis and diuretic activity of compounds structurally related to clopamide]. Farmaco Sci (1987) 0.75
3,8-diazabicyclo--[3.2.1]-octane derivatives as analogues of ambasilide, a Class III antiarrhythmic agent. Eur J Med Chem (2001) 0.75
Rigid congeners of arylpyridazinones. IV. Synthesis and activity of derivatives of the new heterocyclic system 9H-indeno[2,1-c]pyridazine. Farmaco Sci (1985) 0.75
Conformational analysis of phthalein derivatives acting as thymidylate synthase inhibitors by means of 1H NMR and quantum chemical calculations. Bioorg Med Chem (1996) 0.75
[Derivatives of 6-aminopenicillanic acid. V. New semisynthetic penicillins: 1,2-benzisoxazolyl-penicillins]. Farmaco Sci (1965) 0.75
[Effect of diclofenac on the opiate withdrawal syndrome]. G Clin Med (1986) 0.75
[Bicyclic analogues of piperazine. X. (1)-N-Aminoderivatives of 3,8-diazabicyclo-(3.2.1)-octane, 3,8-diazabicyclo-3(3.2.1)-octane-2,4-dione and 2,6-dimethylpiperazine with potential pharmacologic activity]. Farmaco Sci (1972) 0.75
2-(Substituted)amino-2,8-diazaspiro[4,5]decan-1,3-diones as potential muscarinic agonists: synthesis, modeling and binding studies. Drug Des Discov (1996) 0.75
Natural polyhydroxylated compounds as inhibitors of xanthine oxidase. Pharmazie (1996) 0.75
Synthesis and aldose reductase inhibitory activity of a new series of benz[h]cinnolinone derivatives. Farmaco (2000) 0.75
Conformationally restricted congeners of hypotensive and platelet aggregation inhibitors: 6-aryl-5-methyl-4,5-dihydro-3(2H)-pyridazinones derived from 5H-indeno[1,2-c]pyridazine. J Med Chem (1986) 0.75
Circadian variations in plasma ACTH, cortisol and beta-endorphin levels in normal-weight bulimic women. Neuropsychobiology (1996) 0.75
[Derivatives of phenylbutyrates. 3. Synthesis of compounds with potential anti-inflammatory activity correlated to 3,3'-diphenyl-N,N'-dipyrrolidine-2,2'-dione]. Farmaco Sci (1968) 0.75
[Bicyclic homologs of piperazine. 8. Synthesis and characteristics of 3,8-diazabicyclo-(3.2.1.)-octan-2-one]. Farmaco Sci (1969) 0.75
[Pseudohypoparathyroidism. A case complicated by reactive hypoglycemia]. Recenti Prog Med (1985) 0.75
Synthesis, molecular modeling, and opioid receptor affinity of 9, 10-diazatricyclo[4.2.1.1(2,5)]decanes and 2,7-diazatricyclo[4.4.0. 0(3,8)]decanes structurally related to 3,8-diazabicyclo[3.2. 1]octanes. J Med Chem (2000) 0.75